TNIB >>> ACQUIRES PENN STATE RESEARCH FOUNDATION PATENTZZZ
TNI BioTech Acquires Exclusive License To The Portfilio Of Patents Of Dr Ian S. Zagon, Dr. Patricia J. McLauglin And Dr. Jill Smith From The Penn State Research Foundation
BETHESDA, Md., Feb. 1, 2013 /PRNewswire/ -- TNI BioTech, Inc. (TNIB) has signed an exclusive licensing agreement for all of the intellectual property developed at Pennsylvania State by Dr. Ian S. Zagon, Dr. Patricia J. McLaughlin and Dr. Jill P. Smith for the treatment of cancer. The patents cover methods and formulations related to the treatment and prevention of cancers, particularly gastrointestinal cancer. More specifically, the present inventions describe the use of drugs that interact with opioid receptors (naltrexone, naloxone and the pentapeptide growth factor Met-enkephalin) to inhibit and arrest the growth of cancer. Such efficacy has been discovered to be partially due to the functional manipulation of the zeta opioid receptor through exogenous and endogenous Met-enkephalin. This receptor has been determined to be present in a variety of cancers, including pancreatic and colon cancer.
As part of this agreement, TNI BioTech, Inc. is working to acquire the orphan drug designation (IND), and clinical data set from Dr. Jill Smith.
Dr. Ronald Herberman, Chief Medical Officer and Senior Vice President for Research and Development stated, "TNI BioTech is extremely pleased to acquire the exclusive rights to the patent portfolio of the Penn State Research Foundation. Based on the pioneering work of Drs. Ian S. Zagon, Dr. Patricia J. McLaughlin and Dr. Jill P. Smith, these patents are related to the therapeutic efficacy and mechanism of action of Met-enkephalin, referred to as opioid growth factor. These patent acquisitions will help TNI BioTech develop our pipeline for therapy of cancer in conjunction with our other cancer therapies revolving around Met-enkephalin."
Summary of Clinical Trial on the Benefits of OGF in the Treatment of Pancreatic Cancer
In a prospective phase II open-labeled clinical trial performed by Dr. Jill Smith and her colleagues in the Departments of Medicine, Public Health Sciences, Pathology, and Neurosciences and Anatomy at the Pennsylvania State University School of Medicine in Hershey, PA, patients with very advanced pancreatic cancer were treated. These patients had failed prior chemotherapy regimens and were either treated weekly with opioid growth factor (OGF) or entered a hospice program.
Results: Clinical benefit response was experienced by 53% of OGF-treated patients compared to historical controls of 23.8% and 4.8% for gemcitabine and 5-fluorouracil (5-FU), respectively. Of the OGF-treated patients surviving more than eight weeks, 62% showed either a decrease or stabilization in tumor size by computed tomography. The median survival time for the OGF-treated patients was three times that of the untreated hospice patients (65.5 versus 21 days, p < 0.001). No adverse effects on hematologic or chemistry parameters were noted, and quality of life surveys suggested improvement with OGF.
Limitations: Measurements other than survival were not allowed in the control hospice patients, and clinical benefit comparisons were made to historical controls.
Conclusion: OGF biotherapy improves the clinical benefit and prolongs survival in patients with pancreatic cancer by stabilizing disease or slowing progression. The effects of OGF did not adversely alter the patients' quality of life. The use of OGF biotherapy at earlier stages of disease or in combination with chemotherapeutic agents may further improve the outcome of this malignancy.
About TNI BioTech, Inc.
TNI BioTech, Inc., is a biotech company working to combat chronic, life-threatening diseases through the activation modulating the body's immune system using our patented immunotherapy. Our products and immunotherapy technologies are designed to harness the power of the immune system to improve the treatment of cancer, infections such as HIV/AIDS, chronic inflammatory diseases, and autoimmune diseases.
TNI BioTech's proprietary technology, therapies and patents include the treatment of a wide range of cancers. Their most advanced clinical program involves immunotherapy with Methionine Enkephalin (MENK) also termed Opioid Growth Factor (OGF), which has been shown to stimulate the immune system even in patients with advanced cancer.
Even though TNI BioTech considers any condition that results in altered-immune response a target for investigation, they plan to pursue additional investigations for low dose naltrexone and/or MENK as valuable candidates in the treatment of the following:
Autoimmune states such as Crohn's disease, multiple sclerosis and rheumatoid arthritis
As an adjunct in cancer patients undergoing chemotherapy, radiation treatments or surgery
As an adjunct to antibiotics in the treatment of a variety of infectious diseases, including patients with HIV or patients with AIDS, in combination with retroviral drug therapy
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS: This press release includes various "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which represent the Company's expectations or beliefs concerning future events. Statements containing expressions such as "believes," "anticipates," "intends," or "expects," used in the Company's press releases and in Disclosure Statements and Reports filed with the Over The Counter Markets through the OTC Disclosure and News Service are intended to identify forward-looking statements. All forward-looking statements involve risks and uncertainties. Although the Company believes its expectations are based upon reasonable assumptions within the bounds of its knowledge of its business and operations, there can be no assurances that actual results will not differ materially from expected results. The Company cautions that these and similar statements included in this report are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date thereof. The Company undertakes no obligation to publicly release any revisions to such forward-looking statements to reflect events or circumstances after the date hereof.
See http://www.tnibiotech.com for more information.
Contact: Global Investment Media
Phone: 310-353-6277
Posted On: 02/03/2013 7:27:40 PM
Post# of 53447
(0)
(0)
Top 10 Most Recent Blog Posts
Small-Cap Stocks and Dow Outperform Amid Market Rebound
Category: Stocks Total Views: 228
By : Addison Perry Updated: 07-25-2024
Wall Street Indexes Rebound on Strong GDP Data
Thursday's main indexes on Wall Street climbed in response to better than expected GDP data. While the Dow and small-cap stocks lagged, the Nasdaq and S&P corrected early losses. After the tech mauling of the last session, this rise brought relief. On route to recoup Wednesday's losses, the Russell 2000 jumped 2%. Investors questioned whether the recent turn to underperformance made sense. Most megacap stocks were set to prolong losse... Continue Reading
Magnificent Seven Stocks Hit Hard by Earnings Reports
Category: Stocks Total Views: 168
By : Lucas Young Updated: 07-25-2024
Tech Giants' Earnings Disappoint, Sparking Market Selloff
Significant market selloff was started by Tesla and Alphabet's latest earnings releases. Investors worried about Tesla's lowest quarterly profit margin in five years. Anxiety about growing AI infrastructure costs and YouTube competition eclipsed Alphabet's better-than-expected earnings. With a tech-heavy Nasdaq Composite falling 3.6%, its worst day since October 2022. The S&P 500 likewise slumped 2.3%. This response... Continue Reading
SK Hynix Reports Record Profit Driven by AI Chip Demand
Category: Stocks Total Views: 189
By : Evelyn Baker Updated: 07-25-2024
SK Hynix Reports Highest Quarterly Profit Since 2018
SK Hynix declared its highest quarterly profit since 2018. For the quarter April–June, the company declared an operating profit of 5.47 trillion won. From the loss of 2.9 trillion won a year before, this is a notable increase. The profit lines up with LSEG SmartEstimate's projections. Analyzes projected a good performance from SK Hynix. Three straight profitable quarters have come from the company. This represents a notable comeba... Continue Reading
June New Home Sales Drop Despite Easing Mortgage Rates
Category: Real Estate Total Views: 166
By : Owen Jenkins Updated: 07-25-2024
New Home Sales Drop to Seven-Month Low in June
June's sales of newly built single-family homes dropped to a seven-month low. With a 0.6% drop noted by the Census Bureau of the Commerce Department, the seasonally adjusted annual rate comes to 617,000 units. Since November, this represents the lowest level. May's sales pace, on the other hand, was raised from the earlier stated 619,000 units to 621,000 units. This surprising decline in June sales is unambiguous evidence that the recover... Continue Reading
Lineage Raises $4.45B in Historic IPO, Valued at $18B
Category: Stocks Total Views: 169
By : Logan Wright Updated: 07-25-2024
Lineage Achieves Historic IPO with $4.45 Billion Raise
With its U.S. initial public offering, Lineage, the biggest cold-storage warehouse operator in the world, raised $4.45 billion. This is the largest worldwide stock market debut of this year. Pricing almost 57 million shares at $78 apiece comprised the IPO. At the top of its stated range, $70 to $82, this price was The company first intended to offer 47 million shares. Still, great demand resulted in the sale of extra shares. The IPO value... Continue Reading
Private Sector Employment Rises Despite Slower Momentum
Category: Economy Total Views: 328
By : Dylan Bailey Updated: 07-24-2024
U.S. Business Activity Hits 27-Month High in July
July's 27-month high in U.S. business activity suggests strong economic momentum. Rising from 54.8 in June to 55.0, the flash U.S. Composite PMI Output Index from S&P Global Since April 2022 this is the highest level. Tracking both manufacturing and services, the index has a reading above 50 suggesting growth. Driven by notable increases in the services sector, this consistent increase points to robust private sector expansion. The ris... Continue Reading
How to Protect Your Rental Real Estate Investment
Category: Real Estate Total Views: 325
By : Olivia Taylor Updated: 07-24-2024
Introduction to Protecting Your Rental Real Estate Investment
Renting real estate has become a go-to investment strategy these days. It's a good way to earn a consistent income and accumulate long-term wealth.
However, renting a real estate property comes with many risks. Your tenant can file a lawsuit against you, property damage risk and unforeseen circumstances can all spoil your investment success.
Therefore, be proactive in protecting your assets, and ensure a wise rental real ... Continue Reading
Weak Summer Demand, China Slowdown Hit Oil Markets
Category: Markets Total Views: 292
By : Thomas Cooper Updated: 07-24-2024
Oil Prices Edge Higher Amid Canadian Wildfires and Falling U.S. Crude Inventories
Though they stayed close to their six-week low, oil prices slightly rose on Wednesday. Prices started to rise following three consecutive sessions of drop. Falling U.S. crude inventories and supply concerns from Canadian wildfires were mostly responsible for this. September Brent crude futures climbed 66 cents to $81.67 a barrel. September U.S. West Texas Intermediate (WTI) crude rose by 78 cents to $77.74 per b... Continue Reading
Tax Disputes and Litigation: Strategies for Effective Resolution
Category: Personal Finance Total Views: 309
By : Kelly Martin Updated: 07-24-2024
Introduction to Managing and Resolving Tax Disputes
Tax disputes are an unavoidable aspect of business that can arise at any time and involve complex legal and financial issues. Whether it's a dispute over tax returns, audit findings, or tax assessments, the potential implications for a business can be significant, affecting not just financial stability but also the reputation of the company. Preparing effectively can make a substantial difference in the resolution process.
Preparing f... Continue Reading
3 Avoidable Marketing Mistakes Real Estate Startups Can Make
Category: Real Estate Total Views: 309
By : Ryan Hughes Updated: 07-24-2024
Introduction to Effective Marketing Strategies for Real Estate Startups
Starting a business is no easy feat. There’s less comfort in knowing that 90% of startups fail, according to 2024 data sourced from Exploding Topics. The same report found that new business success rates are 10 to 20% over the long term.
The odds against the real estate sector didn’t bode well. About 48% of real estate startups failed within four years. However, there’s still hope for aspiring entrepr... Continue Reading